Company Profile

Spectrum Pharmaceuticals, Inc. is a commercial stage biopharmaceutical company. The Company is focused on acquiring, developing, and commercializing targeted oncology therapies. The Company's product portfolio consists of one commercial product and product candidates for the treatment of cancer patients. Its commercial product candidate includes ROLVEDON (eflapegrastim), which is a long-acting granulocyte colony-stimulating factor (G-CSF) that employs a proprietary LAPSCOVERY technology designed to enhance the duration of therapeutic effects and reduce the frequency of administration. ROLVEDON is FDA-approved for the treatment of adult patients with chemotherapy-induced neutropenia. Its development pipeline includes Poziotinib is a novel, pan-HER inhibitor that is designed to irreversibly block signaling through the Epidermal Growth Factor Receptor (EGFR) family of TKIs, including HER1 (erbB1; EGFR), HER2 (erbB2), HER4 (erbB4), and HER receptor mutations.

Employees

Sector

Biotechnology & Medical Research

More about the company

23-08-04	Top Midday Decliners	MT
23-08-04	Assertio Therapeutics Completes Acquisition of Spectrum Pharmaceuticals, Reports Lower Q2 Adjusted Earnings	MT
23-08-02	Spectrum Pharmaceuticals, Inc.(NasdaqCM:SPPI) dropped from S&P Global BMI Index	CI
23-08-02	Spectrum Pharmaceuticals, Inc.(NasdaqCM:SPPI) dropped from S&P TMI Index	CI
23-08-01	Assertio Holdings Closes Acquisition of Spectrum Pharmaceuticals	MT
23-08-01	Spectrum Pharmaceuticals, Inc. Announces Cessation of Directors	CI
23-08-01	Spectrum Pharmaceuticals, Inc.(NasdaqCM:SPPI) dropped from NASDAQ Composite Index	CI
23-07-30	Assertio Holdings, Inc. (NasdaqCM : ASRT) completed the acquisition of Spectrum Pharmaceuticals, Inc. (NasdaqGS : SPPI).	CI
23-05-17	Spectrum Pharmaceuticals Regains Nasdaq Compliance	MT
23-05-15	Jefferies Downgrades Spectrum Pharmaceuticals to Hold From Buy, Cuts Price Target to $1.50 From $3.50	MT
23-05-09	Spectrum Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	CI
23-05-09	Earnings Flash (SPPI) SPECTRUM PHARMACEUTICALS Reports Q1 Revenue $15.6M	MT
23-05-08	B. Riley Lifts Spectrum Pharmaceuticals' Price Target to $1.14 From $1 on Heels of Announced Sale to Assertio Holdings, Keeps Neutral Rating	MT

23-05-15	Jefferies Downgrades Spectrum Pharmaceuticals to Hold From Buy, Cuts Price Target to $1.50 From $3.50	MT
23-05-08	B. Riley Lifts Spectrum Pharmaceuticals' Price Target to $1.14 From $1 on Heels of Announced Sale to Assertio Holdings, Keeps Neutral Rating	MT
23-04-26	JMP Securities Downgrades Spectrum Pharmaceuticals to Market Perform From Market Outperform	MT
23-04-26	HC Wainwright Downgrades Spectrum Pharmaceuticals to Neutral From Buy	MT
23-04-26	JMP Securities Downgrades Spectrum Pharmaceuticals to Market Perform From Outperform	MT

23-11-22	HER2-mutant Non-Small Cell Lung Cancer Pipeline, Clinical Trials Studies, Emerging Drugs, Mergers and Acquisition, Licensing, Agreements & Collaborations, and Latest News 2023 (Updated)	AQ
23-07-31	Assertio Holdings, Inc. Closes Spectrum Pharmaceuticals Transaction	AQ
23-07-27	Assertio Holdings, Inc. Announces Favorable Vote on Proposed Acquisition of Spectrum Pharmaceuticals	AQ
23-07-20	Independent Proxy Advisory Firms ISS and Glass Lewis Recommend Spectrum Pharmaceuticals Stockholders Vote “FOR” Proposed Transaction with Assertio Holdings, Inc.	BU
23-06-30	SPECTRUM PHARMACEUTICALS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Spectrum Pharmaceuticals, Inc. - SPPI	BU

19-12-27	EN DIRECT DES MARCHES : Groupe ADP, Imerys, Toupargel, Tikehau, Spineway, Amazon.com, Tesla...
19-12-27	Wall Street a encore faim !
16-02-29	Spectrum Pharmaceuticals : Onxeo se renforce dans les cancers orphelins avec DNA Therapeutics
15-06-24	Spectrum Pharmaceuticals : BOURSE-Onxeo monte après la publication des résultats d'une étude
15-06-16	ONXEO : Interview-Onxeo fourbit ses armes pour lutter contre les cancers rares

Date	Insider	Type	Main position	Quantity	% Market Cap.
7/31/23	Keith M. McGahan	Issuer sale	General Counsel	2,300,389	1.1208%
7/31/23	Brittany Bradrick	Issuer sale	Director	113,681	0.0554%
7/31/23	Thomas Riga	Issuer sale	Chief Executive Officer	8,597,579	4.1889%

Spectrum Pharmaceuticals, Inc. Stock

Stocks

SPPI

US84763A1088

Biotechnology & Medical Research

Latest news : Spectrum Pharmaceuticals, Inc.

Analysts' recommendations: Spectrum Pharmaceuticals, Inc.

Press Releases: Spectrum Pharmaceuticals, Inc.

News in other languages: Spectrum Pharmaceuticals, Inc.

Latest insider transactions

Other Biotechnology & Medical Research

Company Profile

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
SPECTRUM PHARMACEUTICALS, INC.	-.--%	+5.64%	-	-	210M
LONZA GROUP AG	+0.99%	+1.78%	+5.07%	+16.49%	49.47B
REVOLUTION MEDICINES, INC.	+3.71%	+9.40%	+486.14%	+579.98%	43.97B
BEONE MEDICINES AG	+5.60%	+10.21%	+20.85%	+81.78%	39.6B
IQVIA HOLDINGS INC.	+2.70%	+1.57%	+32.71%	+9.07%	39.29B
CELLTRION, INC.	+2.21%	+6.75%	+20.20%	+54.40%	32.43B
ASCENDIS PHARMA A/S	+2.23%	+4.71%	-	-	16.84B
MEDPACE HOLDINGS, INC.	+0.97%	+2.35%	+35.99%	+124.45%	16.49B
EUROFINS SCIENTIFIC SE	-0.11%	+2.41%	+5.03%	+20.47%	14.01B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	+0.75%	+15.04%	+79.84%	+29.70%	12.77B
Average	+1.90%	+6.32%	+85.73%	+114.54%	29.43B
Weighted average by Cap.	+2.54%	+6.10%	+105.13%	+138.67%